Fertility preservation in patients with haematological disorders: a retrospective cohort study by Senapati, Suneeta et al.
Fertility preservation in patients with haematological disorders:
a retrospective cohort study☆
Suneeta Senapatia,*, Christopher B Morsea, Mary D Sammela, Jayeon Kimb, Jennifer E
Mersereaub, Brenda Efymowa, and Clarisa R Graciaa
aDepartment of Obstetrics and Gynecology, University of Pennsylvania, United States
bDepartment of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, United
States
Abstract
This study investigated the factors associated with utilization of fertility preservation and the
differences in treatments and outcomes by prior chemotherapy exposure in patients with
haematological diseases. This study included all 67 women with haematological diseases seen for
fertility preservation consultation at two university hospitals between 2006 and 2011. Of the total,
49% had lymphoma, 33% had leukaemia, 7% had myelodysplastic syndrome and 4% had aplastic
anaemia; 46% had prior chemotherapy; and 33% were planning for bone marrow transplantation,
33% pursued ovarian stimulation and 7% used ovarian tissue banking; and 48% of patients did not
pursue fertility preservation treatment. All five cycle cancellations were in the post-chemotherapy
group: three patients with leukaemia and two with lymphoma. Patients with prior chemotherapy
had lower baseline antral follicle count (10 versus 22) and received more gonadotrophins to
achieve similar peak oestradiol concentrations, with no difference in oocyte yield (10.5 versus 10)
after adjustment for age. Embryo yield was similar between those who had prior chemotherapy
and those who had not. Half of the patients with haematological diseases who present for fertility
preservation have been exposed to chemotherapy. While ovarian reserve is likely impaired in this
group, oocyte yield may be acceptable.
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Introduction
Over 130,000 reproductive-age women are diagnosed with cancer in the USA annually
(Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov)
Research Data (1973–2008), National Cancer Institute, DCCPS, Surveillance Research
Program, Cancer Statistics Branch, released April 2011, based on the November 2010
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submission), with haematological cancers accounting for 18% of new diagnoses in women
under the age of 45 (Kohler et al., 2011). In the paediatric and adolescent populations, US
cancer statistics suggest that incidence of leukaemia is increasing 0.5% per year (American
Cancer Society, 2011). While various therapeutic protocols for haematological malignancies
are available, many include alkylating agents which have been associated with
gonadotoxicity and infertility (Meirow and Nugent, 2001). In addition, various non-
malignant haematological disorders such as sickle cell disease require gonadotoxic treatment
strategies similar to those used for haematological malignancies (Bhatia and Walters, 2008;
Walters and Sullivan, 2010). Improvements in treatment regimens have resulted in greater
survival in patients with these disorders, thereby increasing the importance of long-term
quality of life and future fertility to survivors (Letourneau et al., 2011; Loren et al., 2013).
Indeed, studies suggest that the majority of cancer patients are concerned about the risk of
infertility associated with treatment, and a third report that concerns about the risk of
infertility have an impact on their treatment decisions (Partridge et al., 2004).
Over the past decade, there has been increasing interest in methods to expand the
reproductive options of patients facing gonadotoxic therapies. While embryo
cryopreservation is the standard option for adult females with a committed partner, oocyte
cryopreservation is now widely accepted as well; additionally, ovarian tissue
cryopreservation is another experimental option for patients without a committed partner
(Lee et al., 2006). However, patients with haematological disorders present unique
challenges to fertility preservation counselling and management. These individuals are often
too ill at diagnosis to be eligible for fertility preservation treatment, which typically require a
delay in therapy for days to weeks and involve minor surgical procedures, which pose
increased risks in patients with abnormal haematological parameters. Moreover, even if
leukaemia patients are eligible for ovarian tissue cryopreservation, there is concern about
reseeding malignant cells with future autologous transplantation of tissue (Dolmans et al.,
2010; Greve et al., 2012; Mueller et al., 2005; Salle et al., 2003; Schmidt et al., 2011; Shaw
et al., 1996). Leuprolide acetate down-regulation administered prior to chemotherapy is
another option, but the long-term benefits with respect to fertility preservation remain
unclear (Beck-Fruchter et al., 2008; Chen et al., 2011). While patients with lymphoma are
better candidates for fertility preservation treatment, often initial therapies like ABVD
(adriamycin, bleomycin, vincristine and doxorubicin) do not have a substantial risk of
infertility and, therefore, there is less motivation to pursue fertility preservation (Hodgson et
al., 2007). For these reasons, often patients present for fertility preservation consultation
only after a relapse in disease has been diagnosed after initial therapy, and sterilizing stem
cell transplantation has been recommended. Hence, individuals with haematological
malignancies often are seen after having already been exposed to gonadotoxic therapies
(Maltaris et al., 2007).
The American Society of Clinical Oncology has recommended that providers discuss the
fertility risks and fertility preservation options with patients facing gonadotoxic therapies;
however, there are little data on clinical outcomes to guide recommendations for specific
populations (Lee et al., 2006). There is a growing body of evidence regarding fertility
preservation outcomes in breast cancer patients (Azim et al., 2008; Hill et al., 2012;
Letourneau et al., 2011; Oktay et al., 2005, 2006; von Wolff et al., 2011; Westphal and
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Wapnir, 2012); however, the natural course of the disease and treatment are very different
from haematological conditions, making it difficult to extrapolate data to patients with these
disorders. Specifically, there are limited data about the fertility preservation choices and
response to ovarian stimulation for women with haematological malignancies, particularly
for those who have previously been exposed to chemotherapy (Dolmans et al., 2005;
Ginsburg et al., 2001; Klock et al., 2010; Rossi et al., 2011).
The objective of this study was to identify factors that influence the utilization of fertility
preservation treatment in patients with haematological disorders who present for fertility
preservation consultation and to compare fertility preservation treatment choices and ovarian
stimulation parameters between patients who present before or after exposure to
chemotherapy.
Materials and methods
This retrospective cohort study identified all female patients with haematological disorders
who were referred for fertility preservation consultation at two university centres from 2006
to 2011. Institutional Review Board approval was obtained at both study sites before the
start of this study (IRB no. 809406, first approved 16 February 2009, University of
Pennsylvania; 4 August 2009, University of North Carolina Chapel Hill). Patients were
included if they were post-menarchal, had been recently diagnosed with a haematological
disease and had impending chemotherapy treatment.
Medical records were abstracted to obtain detailed demographic and treatment specific data.
Recorded data included: patient age at first fertility preservation consultation, race,
gravidity, parity, body mass index (BMI) and partner status (by patient self-report). Disease
specific information recorded included: haematological diagnosis, treatments prior to
presentation for fertility preservation consultation, the time from last treatment, impending
treatment plans and fertility preservation strategy pursued. For patients who elected to
undergo ovarian stimulation for oocyte or embryo cryopreservation, stimulation parameters
including baseline antral follicle count, cycle day 3–5 FSH, total gonadotrophins used
during stimulation, duration of stimulation, peak serum oestradiol (pg/ml), oocyte yield
(MII), embryo yield and cycle cancellation rates were collected.
Statistical analysis
Baseline characteristics were compared between subjects in different diagnostic categories
and between subjects with and without previous exposure to chemotherapy using Pearson
Chi-squared, Fisher’s Exact and Wilcoxon rank-sum tests for categorical and continuous
data as appropriate. Baseline ovarian reserve and ovarian stimulation parameters were
compared using linear and Poisson regression models, adjusting for age. All hormone
concentrations were transformed using natural log to reduce the influence of a left-skewed
distribution of values. Hormone comparisons between groups are presented as risk ratios of
geometric mean hormone concentrations. Using bootstrap resampling with 50 replicates
drawn from the original samples, 95% confidence intervals (CI) for estimated risk ratios
were obtained. Data analysis was performed using STATA Statistical Software version 12.0.
Two-tailed P < 0.05 was considered statistically significant.
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Results
Cohort characteristics
A total of 67 subjects met inclusion criteria for the study: 44 from the University of
Pennsylvania and 23 from the University of North Carolina Chapel Hill. The baseline
characteristics are presented in Table 1. Haematological diagnoses included: 33 patients
with lymphoma (49%), 22 with leukaemia (33%), five with myelodysplastic syndrome
(7.5%), three with aplastic anaemia (4.5%), two with sickle cell disease, one with multiple
myeloma and pme with Erdheim–Chester disease. Of those with lymphoma, 67% had
Hodgkin’s lymphoma, while amongst those with leukaemia, 41% had acute lymphoblastic
leukaemia, 32% had acute myelogenous leukaemia and 23% had chronic myelogenous
leukaemia (no further specification of diagnosis was available for one patient with
leukaemia). The median age was 25.9 years (range 14–44 years), median BMI was 23.4
kg/m2 (range 17–40 kg/m2) and the majority of the population was Caucasian (79%) with
9% African American, 4.5% Asian and 7.5% representative of other or mixed races. Over
half (57%) of the study population had an intimate partner at the time of fertility
preservation consultation. The majority (73%) were nulligravid and 88% had no living
children. 46% had been exposed to prior chemotherapy and 33% were planning for bone
marrow transplantation (BMT) soon after their initial fertility preservation consultation.
For those who had been exposed to prior chemotherapy, the range of time from last
treatment was from 32 days to 3 years (median 94 days). Prior chemotherapy regimens
included ABVD, R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine and
prednisone), BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine,
procarbazine and prednisone), ABV/COP (doxorubicin, bleomycin, vinblastine,
cyclophosphamide, vincristine and prednisolone), and ICE (ifosfamide, carboplatin and
etoposide) as well as several experimental protocols. There was 26% of patients who had
prior chemotherapy regimens that included an alkylating agent, with cumulative alkylator
scores ranging from 1 to 3 (Green et al., 2009a). Two patients presented after BMT.
After fertility preservation counselling, 25% of the patients opted for embryo
cryopreservation, 7% for oocyte cryopreservation, 3% for ovarian tissue cryopreservation,
6% for some combination of treatments including ovarian stimulation and 9% for leuprolide
acetate down-regulation. One patient who had been planning for isolated pelvic radiation
opted for oophoropexy and 48% decided against fertility preservation methods after
counselling. The median age for opted for fertility preservation management beyond
counselling alone was 26 years (range 14–36 years).
Of the 58 patients for whom impending treatment information was available, 22 patients
(38%) were anticipating treatment with BMT. Patients planning for BMT were significantly
more likely to pursue fertility preservation treatment compared with those who were not
anticipating imminent BMT (17/22, 77% versus 11/44, 25%, P < 0.01, data unavailable for
one patient). Of those who were planning for BMT, 10 patients elected ovarian stimulation
to bank embryos, three patients elected ovarian stimulation to bank oocytes, one patient
elected to bank both ocytes and embryos and one patient elected to bank oocytes and ovarian
tissue. Of note, two patients who attempted ovarian stimulation with the goal of embryo
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cryopreservation had cancelled cycles, one of which subsequently had ovarian tissue
cryopreservation. There were no differences in any of the ovarian stimulation parameters by
diagnosis or planned treatment course.
Fertility preservation choices and outcomes by previous exposure to chemotherapy
Demographic characteristics did not differ between patients who were planning for
chemotherapy compared with those who had already been exposed to chemotherapy with
respect to age, BMI, race, partner status, gravidity or parity (Table 1). The distribution of
cancer diagnoses were similar, and there was no differences in treatment choices overall
between the two groups. There was a trend towards more patients in the post-treatment
group opting to attempt ovarian stimulation, but this failed reach statistical significance
(22% versus 45%).
Of all the women with haematological diseases, 26 patients underwent ovarian stimulation
or a combination of ovarian stimulation and ovarian cryopreservation; 62% (16/26) were in
the post-chemotherapy group. Most of the patients undergoing ovarian stimulation utilized
an antagonist protocol; four patients utilized a protocol with leuprolide acetate down-
regulation with even distribution in the pre-chemotherapy and post-chemotherapy groups.
Of patients who underwent ovarian stimulation in the post-chemotherapy group, 11 out of
14 (79%) reached oocyte retrieval while all of the patients in the pre-chemotherapy group (n
= 10) who attempted stimulation had an oocyte retrieval. All of the cycle cancellations were
patients in the post-chemotherapy group, although this rate did not significantly differ
between patients presenting before versus after chemotherapy, likely due to small sample
size (0% versus 31%). Patients who had cycle cancellation were similar in age compared
with those who did not cancel (median age 25.8 versus 25.8 years), but did have lower
baseline antral follicle counts (4 versus 13, P = 0.04). Of the five patients with cycle
cancellation, three had a diagnosis of leukaemia and two had lymphoma. All underwent
stimulation with antagonist protocols. The most common reason for cancellation was poor
response (4/5, 80%). One patient was cancelled due to exacerbation of a chronic pulmonary
condition on cycle day 2 and cancellation was thus thought to be unrelated to ovarian
stimulation. Two of the patients who where cancelled due to poor response repeated ovarian
stimulation with variable oocytes yields in the second cycle (2 and 10 oocytes). No patients
experienced ovarian hyperstimulation syndrome.
Ovarian reserve and stimulation parameters for cycles in which patients underwent oocyte
retrieval are reported in Table 2. Patients who presented after chemotherapy had
significantly lower baseline antral follicle counts compared with those presenting prior to
chemotherapy (median 10 versus 22, P = 0.01). There was no difference in baseline FSH
concentrations between these two groups (median 4.3 versus 6.0 mIU/ml), but several
patients were on oral contraceptive pills when the assay was performed. When restricting the
analysis to just those patients who were not on ovarian suppression, similar results were seen
(median 7.2 versus 7.6 mIU/ml); however, interpretation of ovarian reserve measures in this
cohort is limited given the small number of patients in this restricted analysis (n = 8). Linear
and Poisson regression modelling with bootstrapping adjusted for age demonstrated that
total days of stimulation, number of follicles greater than 14 mm and peak oestradiol
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concentrations did not significantly differ between the two groups. Patients who had been
exposed to prior chemotherapy required significantly more total gonadotrophins (relative
risk 2.26, 95% CI 1.52–3.38, P < 0.01) to achieve similar oestradiol concentrations with no
difference in oocyte yield between groups (geometric means 9.7 versus 11.3). The post-
chemotherapy group had a wider range of oocyte yield (2–24 oocytes) and had lower
median embryo yield, although this failed to reach statistical significance in age-adjusted
regression modelling. For patients who were post-chemotherapy, time from last treatment
was not significantly associated with any ovarian stimulation parameters.
Discussion
This is one of the first studies to examine both fertility preservation choices and stimulation
parameters in a multicentre cohort of patients with haematological diseases requiring
gonadotoxic therapies. Of patients presenting for fertility preservation consultation, 42%
opted for treatments involving assisted reproduction technology (oocyte, embryo or ovarian
tissue banking), possibly related to the limitations of their disease status at the time of
consultation. This is higher than the use reported in a recent large prospective cohort study,
which reported that 23% of lymphoma patients opted for these fertility preservation
treatments in a population of women referred to one of 70 European centres for fertility
preservation treatment prior to cancer treatment (Lawrenz et al., 2011). Importantly, the use
of ovarian suppression with GnRH agonists was much higher in the European cohort (75%)
compared with that seen in the current study (9%). Also, in this current study, more patients
opted for counselling only (48% versus 16% in the European cohort). These findings may be
attributable to differences in prior chemotherapy exposure and current disease status
between the two cohorts as well as variations on treatment approach in these regions.
It is also important to highlight the fact that almost half of the patients with haematological
diseases who presented for fertility preservation consultation in this study had already been
exposed to potentially gonadotoxic therapies. This phenomenon may be explained by the
fact that many referrals for patients with haematological diseases occur after relapse when
BMT has been recommended. This trend in referral patterns may be due to the narrow
window between initial diagnosis and treatment in patients with leukaemia, often on the
order of hours to days for patients who may be in acute haematological crises. In addition,
while patients with lymphoma have more time available between diagnosis and treatment
compared with patients who present in acute crises, there is often less motivation to pursue
fertility preservation methods since many initial therapies may not pose a major risk to
fertility (Hodgson et al., 2007).
The results of this study indicate that, overall, ovarian reserve is diminished in patients who
present after chemotherapy exposure compared with those who present before treatment and
that patients previously exposed to chemotherapy will have a higher gonadotrophin
requirement but may have similar oocyte yield. The disparate findings between antral
follicle count and baseline FSH are likely due to attenuation of baseline FSH concentrations
by oral contraceptive use in some patients, and incomplete data regarding baseline FSH
concentrations without the influence of ovarian suppression. Serum anti-Müllerian hormone
concentrations may be helpful in assessing ovarian reserve in this patient population in order
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to determine the optimal stimulation protocol, but these data are not available for the current
study. The oocyte yield was quite variable in this group (range 2–24 oocytes), suggesting
that stimulation of previously exposed patients can be unpredictable. Our findings suggest
that use of higher gonadotrophin doses may be prudent.
A recent meta-analysis suggested that women with malignancy and no previous exposure to
chemotherapy should expect a lower number of oocytes retrieved after ovarian stimulation
for fertility preservation compared with healthy age-matched patients, but acknowledged
that this finding did not account for differences by subsets of malignant diagnoses (Friedler
et al., 2012). While the present study did not include a healthy age-matched control group,
its findings are consistent with another study evaluating ovarian stimulation parameters
before and after chemotherapy exposure, which similarly found that patients with
haematological disorders required higher total gonadotrophin doses post-chemotherapy
(Dolmans et al., 2005). However, in contrast to the present findings, another study
demonstrated lower numbers of oocytes retrieved and embryos cryopreserved overall, but
was a heterogeneous population of which haematological malignancies was a small subset
(Klock et al., 2010). The differences seen in the current study may be reflective of the
relatively younger age of patients in the haematological disease cohort.
While the optimal timing of ovarian stimulation after chemotherapy exposure is unknown
and subject to much controversy, the use of fertility preservation treatment in the window
after chemotherapy, before haematopoietic stem cell transplantation has been described
(Rossi et al., 2011). The current study suggests that ovarian stimulation after chemotherapy
may produce acceptable oocyte yields. While data from childhood cancer survivors remote
from therapy indicates that pregnancy outcomes are no different compared with healthy
controls (Green et al., 2009b), animal studies suggest that miscarriage and rates of birth
defects are higher in mice that conceive during chemotherapy exposure (Meirow et al.,
2001). Thus, there is clearly a need to follow pregnancy outcomes from gametes and
embryos obtained after recent exposure to chemotherapy. Patients should be counselled
about the potential risks of ovarian stimulation for oocyte or embryo banking soon after
chemotherapy and that outcomes are not known in this population. While ovarian tissue
cryopreservation is an alternative option for patients with haematological disorders after
exposure to chemotherapy, transplantation is not recommended in patients with leukaemia
due to risk of reseeding cancer cells. The development and improvement of in-vitro
maturation treatment may allow for ovarian tissue cryopreservation to be a realistic option
for having biologic children in the future for these patients.
This study is limited by its relatively small sample size and the heterogeneity of the
population both in terms of haematological diagnoses and their treatments. Therefore, it was
not able to compare stimulation differences between patients exposed to specific
chemotherapeutic regimens. Given that this was retrospective data, it is subject to
information bias, as all data were chart abstracted. There may be a degree of selection bias
with respect to which patients were referred for consultation and treatment: the current study
included all patients who were referred for fertility preservation consultation through
infertility practices and it is difficult to know what proportion of patients this represents
amongst the total population of reproductive-age women with haematological disorders.
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Prospective assessment of multiple centres would be ideal for studying this patient
population. In particular, there is a role for looking at time from diagnosis to consultation
and improving access to fertility preservation services. Finally, and perhaps most
importantly, further studies are needed to assess pregnancy outcomes following the use of
the gametes and embryos with respect to live birth rates, neonatal outcomes and childhood
outcomes before recommendations regarding the optimal treatment strategy can be made.
This study contributes important new data to the growing body of literature regarding the
fertility preservation choices and outcomes of female patients with haematological disorders.
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Table 1
Baseline characteristics by total cohort and chemotherapy exposure.
Characteristic Total cohort Pre-chemotherapy
(n = 36)
Post-chemotherapy
(n = 31)
P-value
Age (years) 25.9 (14–44) 25.5 (14–44) 26 (16–36) NS
Body mass index ((kg/m2) 23.4 (17–40) 23.6 (19–40) 22.9 (17–40) NS
Race (Caucasian)a 53 (79.1) 28 (77.8) 25 (80.6) NS
Presence of partner b 38 (56.7) 19 (52.8) 19 (61.3) NS
Nulligravida 49 (73.1) 25 (69.4) 24 (77.4) NS
Nulliparousa 59 (88.1) 30 (83.3) 29 (93.5) NS
Haematological disorder
  Lymphoma 33 (49.3) 19 (52.8) 14 (45.2) NSc
  Leukaemia 22 (32.8) 8 (22.2) 14 (45.2) NSc
  Myelodysplastic syndrome 5 (7.5) 5 (13.9) 0 (0) NSc
  Aplastic anaemia 3 (4.5) 2 (5.6) 1 (3.2) NSc
  Sickle cell disease 2 (3.0) 1 (2.8) 1 (3.2) NSc
  Multiple myeloma 1 (1.5) 1 (2.8) 0 (0) NSc
  Erdheim–Chester diseasea 1 (1.5) 0 (0) 1 (3.2) NSc
Fertility preservation treatment
  Embryo/oocyte cryopreservation 22 (32.8) 10 (27.8) 12 (38.7) NSc
  Ovarian tissue cryopreservation 2 (3.0) 2 (5.6) – NSc
  Leuprolide acetate 6 (9.0) 5 (13.9) 1 (3.2) NSc
  Oophoropexy 1 (1.5) – 1 (3.2) NSc
  Counselling only 32 (47.8) 19 (52.8) 13 (41.9) NSc
  Combinationa 4 (6.0) – 4 (12.9) NSc
  Planning BMTa 22 (32.8) 7 (20.0) 15 (48.4) 0.02
Values are median (range) tested by Wilcoxon rank-sum test or n (%) tested by aFisher’s Exact test or
b
Chi-squared test (data unavailable for one patient).
c
Fisher’s Exact test for distribution of diagnoses/treatment choice overall, by chemotherapy exposure.
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